Medlab Clinical (ASX: MDC)
Medlab Clinical (ASX: MDC) is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. www.medlab.co
Medlab Clinical’s NanaBis drug dramatically improves cancer bone pain for first patient group in treatment study
Australian biotech Medlab Clinical (ASX: MDC) has reported the first cohort of patients undergoing a 12-month study of its NanaBis cannabinoid t...
Medlab Clinical to be granted European patent for NanoCelle drug delivery platform
Australian biotech Medlab Clinical (ASX: MDC) has announced it has received notice from the European Patent Office of its intention to grant a p...
Medlab Clinical tops up cash reserves, builds board capabilities with new appointment
Medlab Clinical (ASX: MDC) has topped up its cash reserves with a $15 million placement, while boosting its board expertise with the appointment...
Medlab Clinical heads into H2 2021 with strong momentum following ‘very pleasing’ H1
Biotech Medlab Clinical (ASX: MDC) has ended the H1 of the 2021 financial year with $6.8 million cash in the bank with increasing early revenue ...
Medlab Clinical partners with Arrotex to accelerate NanoCBD availability in Australian pharmacies
Medlab Clinical (ASX: MDC) has collared a heads of agreement with Australia’s largest generic over-the-counter (OTC) supplier Arrotex to fast-tr...
Medlab Clinical’s probiotic NRGBiotic found to assist in reducing depression symptoms
Preliminary analysis of a phase IIa trial using Medlab Clinical’s (ASX: MDC) probiotic NRGBiotic has revealed a “significant” reduction in depre...
Medlab Clinical to confirm NanaBis’ potential as non-opioid pain treatment in phase three trials
Australian biotech Medlab Clinical (ASX: MDC) could be the world’s first drug developer to have a registered cannabis-based medicine that outper...
Medlab Clinical collars US FDA IND approval for cancer-pain treatment NanaBis
Medlab Clinical (ASX: MDC) has collared clinical investigational new drug status from the United States Food and Drug Administration for its lea...
Drawbacks of the TGA’s cannabis changes for listed pot stocks
Having been subject to a harsh reality check over the last year or so, the ASX-listed cannabis sector is applauding the local medicine regulator...
Medlab’s NanaBis spray deemed safe for chronic pain management in patients with advanced breast and prostate cancers
Results from an advanced cancer pain clinical trial using NanaBis oro-buccal spray developed by Medlab Clinical (ASX: MDC) has found the novel d...
Medlab trial shows Nanostat spray delivers improved metabolic functioning over tablet version
Australian-based Medlab Clinical (ASX: MDC) has reported results of a bioequivalence trial involving an orobuccal spray version of its Nanostat ...
Export licence granted to Medlab in development of cannabis pain management products
Australian life sciences company Medlab Clinical (ASX: MDC) has been granted a licence to export cannabis relating to the development of its Nan...
Medlab Clinical gets positive feedback from doctors prescribing cannabis for cancer pain
Medlab Clinical (ASX: MDC) has claimed it has received positive feedback from doctors prescribing its cannabis-based medicine NanaBis for the pa...
